Vaxil BioTherapeutics Overview
Vaxil BioTherapeutics is a clinical-stage company developing immunotherapeutic products, including long peptide vaccines and antibodies to treat cancer and infectious diseases. Vaxils products are derived from its fully owned proprietary technology, VaxHit, which uses the signal peptide domains in selected targets as core antigens. The companys lead product, ImMucin, has received EMA and FDA orphan drug designation for the treatment of multiple myeloma (MM) cancer. ImMucin has successfully completed a phase 1/2 clinical trial in 15 MM patients demonstrating a high safety profile and preliminary evidence for clinical efficacy. Vaxil is currently performing an additional phase 1/2 study with ImMucin in metastatic breast cancer patients being treated with first-line hormonal therapy. Vaxil has also isolated SPmAb-2.1 and SPmAb-6, which are anti-MUC1 SP antibodies with therapeutic and diagnostic properties that are potentially superior to other MUC1 antibodies. Vaxil further validated its VaxHit technology for anti-infective indications and isolated MTBuVax, a vaccine against mycobacterium tuberculosis that is currently in preclinical animal studies. Vaxil BioTherapeutics is a fully owned subsidiary of Vaxil Bio.
Cumulative Funding Raised Over Time ($)
$3.0MJul 2013
Latest News
growth-positive
Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover
Vaxil Bio Ltd. and Green Data Center Real Estate Inc. have announced their intention to complete a business combination or similarly structured transaction, constituting a reverse takeover of Vaxil. The transaction is subject to regulatory approval and standard closing conditions. In connection with the transaction, Green Data intends to complete a private placement for gross proceeds of a minimum of C$2,000,000. The transaction is expected to be completed by June 28, 2024. Post-transaction, the resulting issuer will carry on the business of Green Data.
AcquisitionPublic Trading
growth-positive
Vaxil Provides Business Update on Corvax™ Experiments
Vaxil Bio Ltd. has completed the manufacturing of its Corvax product for a research project with the US Army Medical Research Institute of Infectious Diseases. The first Corvax injections in mice are expected to be administered in December 2020. The company has also initiated an exploratory pre-clinical study to determine the viability of administering Corvax orally, with results anticipated in January 2021. Both experiments are being financed from existing working capital. Vaxil Bio is an Israeli immunotherapy biotech company focused on targeting cancer markers and infectious diseases. Its lead product, ImMucin, has completed a Phase 1/2 clinical trial for multiple myeloma. The company aims to develop ImMucin as a COVID-19 and tuberculosis vaccine/treatment. Vaxil Bio utilizes signal peptide domains to develop targeted therapies and its proprietary bioinformatic approach, VaxHit, to identify these domains.
Investment
growth-positive
Vaxil Initiates Pre-Clinical Study in New Oncology Target
Vaxil Bio Ltd. has announced the initiation of a pre-clinical program for ImMucin™ in combination with the E-selectin binding polymer-based therapeutic (P-Esbp). The program will be led by Prof. Ayelet David from Ben-Gurion University of the Negev, Israel. The partnership aims to assess the potential of ImMucin and P-Esbp for the treatment of solid tumors, including breast and ovarian cancer. Vaxils Chairman and CEO, David Goren, expressed excitement about the program and its potential impact on cancer immunotherapy. The pre-clinical program will run for the next year and a half, after which the results will be evaluated for potential clinical trials. The program will be supported by the companys existing working capital. Vaxil Bio is also continuing to advance its potential COVID-19 vaccine, CorVax™.
Partners
growth-positive
Vaxil Announces Positive Results on CorVax™ in vivo Study
Vaxil Bio Ltd., an immunotherapy biotech company, has achieved positive results for an in vivo immunogenicity study of its COVID-19 vaccine candidate, CorVax™. The study, conducted at the Tel Aviv Sourasky Medical Centre in Israel, demonstrated both cellular and humoral responses to the vaccine. The results confirm the potential of Vaxils vaccine candidate and provide evidence of its ability to generate an immune response. The company plans to continue producing more data and eventually seek approval to launch a clinical trial. Vaxils collaboration with the Tel Aviv Sourasky Medical Centre has been effective, and the study results are expected to be published in the future. The company expects to provide a further update within the next eight weeks.
InvestmentExpand
growth-positive
Vaxil Provides Update on Preclinical Experiment
Vaxil Bio Ltd., an immunotherapy biotech company, has shared the results of its first preclinical experiment for its COVID-19 vaccine candidate. The experiment validated the immune response of the vaccine candidate and demonstrated positive results in T cell population and specific subpopulations. The companys peptides have the potential to elicit both a T cell and B cell immune response, making it a promising preventive vaccine. Vaxil has already begun the next set of experiments in its preclinical program to further understand immune responses and determine dosing. The company aims to play a role in developing multiple vaccination strategies to meet the global demand for COVID-19 vaccines.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6M |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 3 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | vaxil-bio.com/cgi-sys/suspendedpage.cgi |
Locations
Pinhas Sapir Street 3, Ness Ziona, Israel
100 King Street West, Toronto, ON, Canada
Photos & Videos
2 item(s)
Vaxil BioTherapeutics Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsTags (12)
immunologybiotechnologytherapeuticsbiopharmaceuticalpublic-healthcancerinfectious-diseaseoncologypharmaceuticalscancer-therapypharma-companiesvaccinesGeographic Markets
IsraelCanadaUnited StatesVaxil BioTherapeutics Financials
$6M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Mature
Funding stage
3
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$3.0MJul 2013
Private Equity Funding
Undisclosed Round
Jul 2013
$3M
Yorkville Advisors
Public Offering / Exit
DelistingEvent
Jul 2016
Undisclosed
POEvent
Mar 2016
Undisclosed
POEvent
Feb 2016
Undisclosed
Vaxil BioTherapeutics Lifecycle
Cumulative Funding Raised Over Time
$3.0MJul 2013
All Events
Undisclosed Round
Jul 2013
$3M
Yorkville Advisors
DelistingEvent
Jul 2016
Undisclosed
POEvent
Mar 2016
Undisclosed
POEvent
Feb 2016
Undisclosed
Vaxil BioTherapeutics News
10 articles
growth-positive
Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover
Vaxil Bio Ltd. and Green Data Center Real Estate Inc. have announced their intention to complete a business combination or similarly structured transaction, constituting a reverse takeover of Vaxil. The transaction is subject to regulatory approval and standard closing conditions. In connection with the transaction, Green Data intends to complete a private placement for gross proceeds of a minimum of C$2,000,000. The transaction is expected to be completed by June 28, 2024. Post-transaction, the resulting issuer will carry on the business of Green Data.
AcquisitionPublic Trading
growth-positive
Vaxil Provides Business Update on Corvax™ Experiments
Vaxil Bio Ltd. has completed the manufacturing of its Corvax product for a research project with the US Army Medical Research Institute of Infectious Diseases. The first Corvax injections in mice are expected to be administered in December 2020. The company has also initiated an exploratory pre-clinical study to determine the viability of administering Corvax orally, with results anticipated in January 2021. Both experiments are being financed from existing working capital. Vaxil Bio is an Israeli immunotherapy biotech company focused on targeting cancer markers and infectious diseases. Its lead product, ImMucin, has completed a Phase 1/2 clinical trial for multiple myeloma. The company aims to develop ImMucin as a COVID-19 and tuberculosis vaccine/treatment. Vaxil Bio utilizes signal peptide domains to develop targeted therapies and its proprietary bioinformatic approach, VaxHit, to identify these domains.
Investment
growth-positive
Vaxil Initiates Pre-Clinical Study in New Oncology Target
Vaxil Bio Ltd. has announced the initiation of a pre-clinical program for ImMucin™ in combination with the E-selectin binding polymer-based therapeutic (P-Esbp). The program will be led by Prof. Ayelet David from Ben-Gurion University of the Negev, Israel. The partnership aims to assess the potential of ImMucin and P-Esbp for the treatment of solid tumors, including breast and ovarian cancer. Vaxils Chairman and CEO, David Goren, expressed excitement about the program and its potential impact on cancer immunotherapy. The pre-clinical program will run for the next year and a half, after which the results will be evaluated for potential clinical trials. The program will be supported by the companys existing working capital. Vaxil Bio is also continuing to advance its potential COVID-19 vaccine, CorVax™.
Partners
growth-positive
Vaxil Announces Positive Results on CorVax™ in vivo Study
Vaxil Bio Ltd., an immunotherapy biotech company, has achieved positive results for an in vivo immunogenicity study of its COVID-19 vaccine candidate, CorVax™. The study, conducted at the Tel Aviv Sourasky Medical Centre in Israel, demonstrated both cellular and humoral responses to the vaccine. The results confirm the potential of Vaxils vaccine candidate and provide evidence of its ability to generate an immune response. The company plans to continue producing more data and eventually seek approval to launch a clinical trial. Vaxils collaboration with the Tel Aviv Sourasky Medical Centre has been effective, and the study results are expected to be published in the future. The company expects to provide a further update within the next eight weeks.
InvestmentExpand
growth-positive
Vaxil Provides Update on Preclinical Experiment
Vaxil Bio Ltd., an immunotherapy biotech company, has shared the results of its first preclinical experiment for its COVID-19 vaccine candidate. The experiment validated the immune response of the vaccine candidate and demonstrated positive results in T cell population and specific subpopulations. The companys peptides have the potential to elicit both a T cell and B cell immune response, making it a promising preventive vaccine. Vaxil has already begun the next set of experiments in its preclinical program to further understand immune responses and determine dosing. The company aims to play a role in developing multiple vaccination strategies to meet the global demand for COVID-19 vaccines.
InvestmentExpand
growth-positive
VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT
Vaxil Bio Ltd., an immunotherapy biotech company, has provided an update on its COVID-19 research program. The company has successfully identified a COVID-19 vaccine candidate based on its proprietary technology and in vivo experiments. They have now begun executing their preclinical program to test the efficacy of the vaccine candidate. Vaxil Bio has also applied for an additional patent to provide coverage for a broader set of vaccine candidates. The company has received aggregate proceeds of $1,047,000 from the exercise of previously issued warrants, which will be used to advance their research program. Vaxil Bio is focused on developing targeted therapies against cancer and infectious diseases using its unique approach. The company cautions that COVID-19 vaccine development is still in the early stages and makes no claims about its ability to eliminate the virus at this time.
Investment
growth-positive
Vaxil Announces the Identification of a Potential Corona Virus Vaccine and Provides an Update in the Previously Announced Debt Financing
Vaxil Bio Ltd., an immunotherapy biotech company, has successfully identified a COVID-19 vaccine candidate based on unique signal peptide technology. The company plans to initiate manufacturing and testing while exploring partnerships. They also anticipate closing a private placement for convertible debentures. Vaxil is focused on developing targeted therapies for cancer and infectious diseases using signal peptide domains and monoclonal antibodies. Their lead product, ImMucin™, has completed a Phase 1/2 clinical trial and received orphan drug status. The company aims to leverage their bioinformatic approach, VaxHit™, to develop effective treatments. The TSX Venture Exchange has not approved the contents of the press release.
PartnersInvestment
growth-positive
Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy Treatment
Vaxil Bio Ltd., a cancer research biotechnology company, has been granted a patent from the Indian Patent Office for its ImMucinTM cancer immunotherapy. The patent provides broad coverage for Vaxils lead product, ImMucinTM, in key jurisdictions around the globe. ImMucinTM is an immunotherapy treatment that trains and harnesses cancer patients immune systems to attack cancer cells. Vaxil has also obtained patents in the United States, the European Union, Canada, Australia, Israel, and India. The company is focused on advancing the manufacturing processes for ImMucinTM and is in discussions with experts regarding Chemistry, Manufacturing and Controls (CMC) for production. Vaxil aims to produce larger quantities of high-quality product to enable additional clinical trials. The companys goal is to enhance its ability to produce ImMucinTM efficiently and embark on more clinical trials.
Investment
growth-positive
New Israeli Cancer Vaccine Triggers Response In 90% Of Cancer Types
Israeli biotechnology company Vaxil BioTherapeutics is developing a vaccine for cancer called ImMucin, which is designed to prevent the disease from returning. The vaccine triggers a response in about 90% of all types of cancer. It is not a replacement for traditional cancer treatments, but targets the early stages of detection and during remission. The company has conducted successful clinical trials on multiple myeloma and breast cancer patients. Vaxils most recent valuation is just under $3 million, and the company is confident that ImMucin will be on the market by the end of the decade.
Customers
N/A
Vaxil Reports Positive Results From a Phase I/II Clinical Trial Using Its Therapeutic Cancer Vaccine, ImMucin, In Patients With Multiple Myeloma
The article does not provide any relevant information or news about GlobeNewswire.
Vaxil BioTherapeutics Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 4 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Vaxil BioTherapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 93/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513861351 |
| Crunchbase | vaxil-biotherapeutics |
| Phone | +97289396948 |
| Last updater | Paul Weisko |
| Updater email | pweisko@gmail.com |
| Last update | 2021-03-04T00:00:00.000Z |
| Created | 2014-11-24T00:00:00.000Z |
| Status detail | Public on TASE on Mar, 2016<br> |